Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, scottsmith, ZROYPU
Search This Board: 
Last Post: 5/25/2018 9:02:42 AM - Followers: 755 - Board type: Free - Posts Today: 31

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

2017 MILESTONES:



Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

Cannabis Report
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Quarterly Report (10-q) 05/10/2018 04:14:20 PM
IPIX News: Traders News Issues Research on High Growth Canna and Pharma Stocks 04/25/2018 08:00:00 AM
IPIX News: Current Report Filing (8-k) 04/16/2018 01:18:08 PM
IPIX News: Current Report Filing (8-k) 04/09/2018 03:04:31 PM
IPIX News: Quarterly Report (10-q) 02/07/2018 04:59:15 PM
PlusOneCoin Top Posts
#228085   The need for sudden cash could have been KarinCA 05/13/18 01:01:34 PM
PostSubject
#228693  Sticky Note The right? Leo has a fiduciary responsibility scottsmith 05/18/18 09:09:13 AM
#228144  Sticky Note Escrow comes to mind. Or maybe they're BooDog 05/14/18 08:06:48 AM
#226931  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 05/06/18 09:45:43 PM
#226822  Sticky Note Brilacidin-OM in the News: Oral Mucositis Market Untapped—Framed BooDog 05/04/18 04:47:53 PM
#226817  Sticky Note BP's interests in the Big Three sox040713 05/04/18 04:17:49 PM
#229273   Dear dUd day five of your “it will video6972 05/25/18 09:02:42 AM
#229272   I think an argument could be made for Detonate 05/25/18 08:52:38 AM
#229271   Better than I thought yes. Ready to start BooDog 05/25/18 08:50:26 AM
#229269   I stopped reading after this first sentence. Detonate 05/25/18 08:32:12 AM
#229264   Today's forecast is 25k volume with not a tombrady12nh 05/25/18 07:57:31 AM
#229261   Great work as always petemantx! LilyGDog 05/25/18 07:43:57 AM
#229260   If the bunnysquirrel is just quirky the duck video6972 05/25/18 07:42:07 AM
#229258   Stay vigilant and stay patient. Leo and scottsmith 05/25/18 07:40:14 AM
#229257   FIVE....WHATTTTTTT?.......he added three more last week ? WILD_4_IPIX 05/25/18 07:39:42 AM
#229256   A banker... don’t make me laugh. bradfordbros 05/25/18 07:38:43 AM
#229254   No news is bad news. How long can To infinity and beyond! 05/25/18 07:23:02 AM
#229253   169/159- ok we will skip ahead to Tuesday, To infinity and beyond! 05/25/18 07:13:27 AM
#229252   EXCELLENT PETE....Thanks Pal and of course he lost WILD_4_IPIX 05/25/18 07:07:30 AM
#229251   TIAB Look at how much money those 20 pharmas Echo20 05/25/18 06:56:17 AM
#229250   That's when I cut my shares by NanoEngineer 05/25/18 06:44:06 AM
#229249   A piece on bio tech at this time: Echo20 05/25/18 06:42:59 AM
#229248   Thanks for the update. I'm not sure about loanranger 05/25/18 06:20:02 AM
#229247   maz......do you understand the meaning of libelous statements??? falcon74 05/25/18 12:55:43 AM
#229246   The "right-to-try" legislation is meant for terminally ill Blues44 05/25/18 12:37:09 AM
#229245   Scotty.....that last post of yours might be the falcon74 05/25/18 12:35:55 AM
#229243   DITTO!!! glta choctaw 05/25/18 12:08:03 AM
#229242   Truer Words Have Never Been Spoken. Keep up Here Today 05/24/18 11:59:41 PM
#229241   Agree green is good 05/24/18 11:58:25 PM
#229235   Intermittent. Fortunately. BooDog 05/24/18 10:53:48 PM
#229234   Just file your civil suit against Leo and lousy engineer 05/24/18 10:53:00 PM
#229230   I'm in. arvitar 05/24/18 10:30:34 PM
#229227   Now that's what I call Doing some serious Here Today 05/24/18 09:53:31 PM
#229225   That's easier to reply to. I do BooDog 05/24/18 09:12:46 PM
#229224   BooDog, In response to post kfcyahoo 05/24/18 09:05:38 PM
#229221   The more fundamental question is not when will scottsmith 05/24/18 08:31:32 PM
#229220   Once again,BS talks and BS walks. keltoi 05/24/18 08:25:24 PM
#229217   When Will Leo secure a deal. This is Williamsc 05/24/18 08:01:29 PM
#229216   Actually my posts have been upgraded from rated scottsmith 05/24/18 07:53:00 PM
#229215   New investors, the statement “54% of today's volume sox040713 05/24/18 07:39:52 PM
#229214   Market cap agrees with me. And that scottsmith 05/24/18 07:26:38 PM
#229213   Still quirky. petemantx 05/24/18 07:12:01 PM
#229212   Good post. And if that's how one thinks/looks Blues44 05/24/18 07:06:39 PM
#229211   FINRA short sales of IPIX AlanC 05/24/18 07:02:16 PM
#229210   Just to let everyone know, Leo has not Cassius Longinus 05/24/18 06:47:19 PM
#229209   shocking lack of faith in the company. To infinity and beyond! 05/24/18 06:44:09 PM
#229208   I know I've made good money here. Looking BooDog 05/24/18 06:43:42 PM
#229207   Anybody think there’s still hope of seeing p snayeman 05/24/18 06:36:06 PM
#229206   These type of Penny Sleds (from my experience) TheBunny 05/24/18 06:17:34 PM
#229205   No way this post is rated 'PRO'! taas 05/24/18 06:08:42 PM
#229204   Bullshit Scotty. Four or five malcontents does not 58nout 05/24/18 06:00:50 PM
#229203   You speak for most of us. Leo scottsmith 05/24/18 05:41:31 PM
#229202   I did as you suggested and went back petemantx 05/24/18 05:05:06 PM
#229201   - Leo Ehrlich is a fraud with a maz100577 05/24/18 04:48:46 PM
#229200   BooDog, Your loyal to the company- that is for kfcyahoo 05/24/18 04:42:51 PM
#229198   tass, If you have read my past posts TheBunny 05/24/18 04:13:56 PM
PostSubject